Clinical Data's Q4 Revenue Doubles as Net Loss Widens
June 15, 2009
Clinical Data's Q4 Revenue Doubles as Net Loss Widens
Fourth-quarter R&D spending rose 140 percent to $12.8 million from $5.3 million for the same period in fiscal 2008. Clinical Data said that the increase was driven by Phase III confirmatory clinical and safety trials for vilazodone, the company's drug candidate for depression.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Cepheid Reports Q4, FY '12 Revenue Growth, but Looks to Address Issues from 'Challenging' Year
January 31, 2013 / PCR Insider - Sequenom Collects 18K Samples for MaterniT21 Plus in Q3, Expects to Bill for Over 50K Tests in 2012
November 14, 2012 / Clinical Sequencing News - Gen-Probe Tallies Record Revenues in Q4 2011 as Aptima Tests, Blood Screening Thrive
February 16, 2012 / PCR Insider - Increasing Investment in Next-Gen Sequencing, Genomic Health Takes $2.8M Stake in Two Startups
May 4, 2011 / Clinical Sequencing News - Complete Genomics Sees Future in Cancer Genome Sequencing; Plans New Cancer-Specific Product
March 16, 2011 / Clinical Sequencing News